Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are associated with disease-initiating stem cells that are not eliminated by conventional therapies. Transcriptomic analysis of stem and progenitor populations in MDS and AML demonstrated overexpression of STAT3 that was validated in a...

Full description

Bibliographic Details
Main Authors:	Shastri, A, Choudhary, G, Teixeira, M, Gordon-Mitchell, S, Ramachandra, N, Bernard, L, Bhattacharyya, S, Lopez, R, Pradhan, K, Giricz, O, Ravipati, G, Wong, L, Cole, S, Bhagat, T, Feld, J, Dhar, Y, Bartenstein, M, Thiruthuvanathan, V, Wickrema, A, Ye, B, Frank, D, Pellagatti, A, Boultwood, J, Zhou, T, Kim, Y, Macleod, A, Epling-Burnette, P, Ye, M, McCoon, P, Woessner, R, Steidl, U, Will, B, Verma, A
Format:	Journal article
Language:	English
Published:	American Society for Clinical Investigation 2018

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells

Similar Items